Drug intelligence / Profile preview

AZD0708

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

**AZD0708** is an investigational oral small-molecule PCSK9 inhibitor developed by AstraZeneca for hypercholesterolemia. It binds to a novel pocket in the PCSK9 C-terminal domain, inhibiting lysosomal trafficking of the PCSK9-LDLR complex to prevent LDLR degradation and enhance LDL clearance. In early clinical studies, it achieved up to 52% LDL-C reduction when added to rosuvastatin.[8]

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on AZD0708.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD0708.

Explore the full profile